AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies ...

After LAMA/LABA/ICS in a single inhaler was introduced in late 2017, researchers found rises in the number of patients prescribed this therapy with each new year (2018, 3%; 2019, 8%; 2020, 11% ...

The hawks want everyone with group E COPD to receive triple therapy including ICSs, whereas the doves see a role for LAMA/LABA and targeting by eosinophils. The dove who wrote the con paper argues ...

A long-acting muscarinic antagonist plus long-acting beta agonist (LABA) was linked to fewer COPD exacerbations and pneumonia hospitalizations vs. an inhaled corticosteroid and LABA, according to ...

Vandana Singh March 4, 2025 at 1:20 PM Copied GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report ...

Clinical trials nebulized formoterol fumarate: Long-term and cardiovascular safety COPD Data from 2 clinical safety trials included in NDA filing for Perforomist Inhalation Solution provided at ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

The most prescribed inhaler regimen was the guideline-concordant combination LAMA + LABA + ICS (15,574; 46.1%), followed by the guideline-discordant regimen ICS + LABA (7884; 23.3%) and short ...

New users of LAMA-LABA therapy had a 20% reduction in the rate of first pneumonia hospitalization compared with new users of ICS-LABA (HR, 0.80; 95% CI, 0.75-0.86).

Pulmonology > COPD Generic Fluticasone–Salmeterol Inhaler for COPD Matches Branded Product — Similar incidences of exacerbation, pneumonia hospitalization between inhalers by Elizabeth Short ...

The Impact of Tiotropium on Mortality and Exacerbations When Added to Inhaled Corticosteroids and Long-Acting Beta-Agonist Therapy in COPD Short PM, Williamson PA, Elder DH, Lipworth SI, Schembri ...

Key Topics Covered: EXECUTIVE SUMMARY MARKET CONTEXT - While traditional first-line medications face generic competition, pipeline triple combinations and LABA/LAMAs will fuel modest growth in COPD ...